Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 12 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Myelodysplastic syndromesThis series is part of our curated briefing on it.
- Samples
- 12 samples: 12 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and DecitabineClinical cancer research : an official journal of the American Association for Cancer Research · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE312447_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1373333. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 12 sample titles: 12 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9346063 CMML Patient 5 BMMNC timepoint 1 (scRNA-seq)
- GSM9346064 CMML Patient 5 BMMNC timepoint 1 (scATAC-seq)
- GSM9346065 CMML Patient 5 BMMNC timepoint 2 (scRNA-seq)
- GSM9346066 CMML Patient 5 BMMNC timepoint 2 (scATAC-seq)
- GSM9346067 CMML Patient 5 BMMNC timepoint 3 (scRNA-seq)
- GSM9346068 CMML Patient 5 BMMNC timepoint 3 (scATAC-seq)
- GSM9346069 CMML Patient 5 BMMNC timepoint 4 (scRNA-seq)
- GSM9346070 CMML Patient 5 BMMNC timepoint 4 (scATAC-seq)
- GSM9346071 CMML Patient 6 BMMNC timepoint 1 (scRNA-seq)
- GSM9346072 CMML Patient 6 BMMNC timepoint 1 (scATAC-seq)
- GSM9346073 CMML Patient 6 BMMNC timepoint 2 (scRNA-seq)
- GSM9346074 CMML Patient 6 BMMNC timepoint 2 (scATAC-seq)
- GSE21991 Myelodysplastic/myeloproliferative neoplasms 156 samples same disease briefing · shares neoplasms
- GSE31174 Affymetrix SNP array data for myelodysplastic syndromes (MDS) and related neoplasms 58 samples same disease briefing · shares neoplasms
- GSE326589 Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS 58 samples same disease briefing · shares decitabine
- GSE236535 Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms 9 samples same disease briefing · shares neoplasms
- GSE284647 The genotype-integrated gene expression profile at the single-cell level of bone marrow CD34-positive hematopoietic stem and progenitor cells (HSPCs) from a patient with myelodysplastic neoplasms (MDS) harboring germline and somatic DDX41 variants. 1 samples same disease briefing · shares neoplasms
- GSE264117 Investigating microenvironment in MDS II 503 samples same disease briefing
- GSE298020 PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression. 493 samples same disease briefing
- GSE256396 Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower risk myelodysplastic syndromes 374 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.